Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

Abstract Background Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) disease. Adiponectin is involved in the metabolism of glucose and lipids with favourable effects on CV disease, especially its high molecular weight (HMW) isoform. Body composition changes are d...

Full description

Bibliographic Details
Main Authors: Eric Toussirot, Hubert Marotte, Denis Mulleman, Grégoire Cormier, Fabienne Coury, Philippe Gaudin, Emmanuelle Dernis, Christine Bonnet, Richard Damade, Jean-Luc Grauer, Tassadit Ait Abdesselam, Caroline Guillibert-Karras, Frédéric Lioté, Pascal Hilliquin, Antoinette Sacchi, Daniel Wendling, Benoît Le Goff, Marc Puyraveau, Gilles Dumoulin
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Arthritis Research & Therapy
Subjects:
Adiponectin
Cardiovascular risk
Rheumatoid arthritis
Tocilizumab
Body composition
Online Access:http://link.springer.com/article/10.1186/s13075-020-02297-7

Internet

http://link.springer.com/article/10.1186/s13075-020-02297-7

Similar Items